drugset / Trial / NCT06145607

A Phase 1 Study Assessing the Effect of Food on the Pharmacokinetics of ABBV- CLS-7262

NCT06145607

Phase 1 Completed 18 enrolled Calico Life Sciences LLC AbbVie · collab
NaSingle-groupOpen-labelTreatment

Summary

This study is a randomized, three period, six sequence, single dose crossover design with ABBV-CLS-7262 in healthy adult subjects.

Timeline

Start
2023-12-19
Primary completion
2024-01-30
Completion
2024-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-CLS-7262 Unknown

Indications

No indication recorded.